5.42
-0.1106(-2.00%)
Currency In USD
| Previous Close | 5.53 |
| Open | 5.55 |
| Day High | 5.71 |
| Day Low | 5.14 |
| 52-Week High | 14.36 |
| 52-Week Low | 4.59 |
| Volume | 44,427 |
| Average Volume | 16,657 |
| Market Cap | 10.38M |
| PE | -0.21 |
| EPS | -26.42 |
| Moving Average 50 Days | 5.45 |
| Moving Average 200 Days | 7.5 |
| Change | -0.11 |
If you invested $1000 in Bolt Biotherapeutics, Inc. (BOLT) since IPO date, it would be worth $8.43 as of September 29, 2025 at a share price of $5.42. Whereas If you bought $1000 worth of Bolt Biotherapeutics, Inc. (BOLT) shares 3 years ago, it would be worth $183.11 as of September 29, 2025 at a share price of $5.42.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates
GlobeNewswire Inc.
May 08, 2025 12:00 PM GMT
Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a biopharmaceutical company developing novel immunotherapies for the tre
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025
GlobeNewswire Inc.
Apr 30, 2025 8:05 PM GMT
CEA-targeted ISAC elicits complete responses in mice and is well-tolerated in NHPs PD-L1 ISAC directly activates and reprograms PD-L1-expressing myeloid cells in the TME to drive complete responses and immunological memory REDWOOD CITY, Calif., April
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
GlobeNewswire Inc.
Apr 25, 2025 5:00 PM GMT
BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events BDC-3042 showed biological activity, with clear dose-dependent increases in proinflammatory cytokines and chemokines BDC-3042 s